Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, on May 17, 2024. The report covers events occurring on May 13, 2024. The company is headquartered in San Diego, California, and its common stock and warrants trade on the NYSE American LLC under the symbols CLDI and CLDIWS, respectively.
Key Financial Metrics
This filing does not contain periodic financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change disclosed in this filing relates to executive compensation adjustments approved by the Compensation Committee on May 13, 2024, effective immediately:
- Base Salary Increase: Wendy Pizarro's annualized base salary was increased by $25,000 to a new total of $425,000.
- Bonus Target Adjustment: The annual discretionary bonus target was increased from 30% to 40% of her base salary.
- Contingent Bonus: Ms. Pizarro is eligible for a one-time bonus of $120,000 contingent upon the Company closing a $10 million debt or equity financing round on or before December 31, 2024. The final amount is subject to determination by the Chief Executive Officer based on Ms. Pizarro's involvement and support.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, general outlook, or specific risk factors beyond the context of the compensation adjustment. The contingent bonus structure implies a strategic focus on securing $10 million in capital by the end of 2024, though no explicit probability or timeline for this event is guaranteed in the text.
Key Facts for Investor Verification
- Verify the current cash position and runway of Calidi Biotherapeutics to assess the likelihood of closing the $10 million financing round required for the contingent bonus.
- Review the company's recent capital raising activities to determine if the $10 million target is feasible by December 31, 2024.
- Confirm the total number of outstanding shares and warrants to understand the potential dilution impact if the equity portion of the financing is executed.
- Monitor future filings for the actual execution of the financing round and the subsequent payout of the contingent bonus.